{{medical}}
{{NoteTA|G1=Chemistry|G2=Medicine}}
{{Drugbox
| Verifiedfields = changed
| verifiedrevid = 464192413
| IUPAC_name = 2-(2-<nowiki/>{4-[(''R'')-(4-chlorophenyl)(phenyl)methyl]piperazin-1-yl}ethoxy)acetic acid
| image = Levocetirizine structure 2.svg
| width = 280
| image2 = Levocetirizine 3D ball.png
| alt2 = Ball-and-stick model of the levocetirizine molecule
<!--Clinical data-->
| tradename = Xyzal, Levazyr
| Drugs.com = {{drugs.com|monograph|levocetirizine-dihydrochloride}}
| MedlinePlus = a607056
| pregnancy_AU =  
| pregnancy_US = B
| pregnancy_category =  
| legal_AU =  
| legal_UK = POM
| legal_US = Rx-only
| routes_of_administration = Oral

<!--Pharmacokinetic data-->
| bioavailability = 高
| protein_bound = 90%
| metabolism = [[肝臟|肝臟]] 14% [[CYP3A4|CYP3A4]]
| elimination_half-life = 6 至 10 小時
| excretion = [[腎|腎]]及[[糞便|排泄物]]

<!--Identifiers-->
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 130018-77-8
| ATC_prefix = R06
| ATC_suffix = AE09
| PubChem = 1549000
| IUPHAR_ligand = 1214
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 1266001
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 6U5EA9RT2O
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D07402
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 1201191

<!--Chemical data-->
| C=21 | H=25 | Cl=1 | N=2 | O=3 
| molecular_weight = 388.888 g/mol
| smiles = Clc1ccc(cc1)[C@H](N2CCN(CCOCC(=O)O)CC2)c3ccccc3
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C21H25ClN2O3/c22-19-8-6-18(7-9-19)21(17-4-2-1-3-5-17)24-12-10-23(11-13-24)14-15-27-16-20(25)26/h1-9,21H,10-16H2,(H,25,26)/t21-/m1/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = ZKLPARSLTMPFCP-OAQYLSRUSA-N
}}

'''鹽酸左西替利嗪'''（{{lang-en|Levocetirizine}}），又稱：Xyzal、驅異樂。是第三代[[抗組織胺藥|抗組織胺藥]]，<ref name="AAAAI/ACAAI Guidelines">{{cite journal | vauthors = Wallace DV, Dykewicz MS, Bernstein DI, Blessing-Moore J, Cox L, Khan DA, Lang DM, Nicklas RA, Oppenheimer J, Portnoy JM, Randolph CC, Schuller D, Spector SL, Tilles SA | title = The diagnosis and management of rhinitis: an updated practice parameter | journal = The Journal of Allergy and Clinical Immunology | volume = 122 | issue = 2 Suppl | pages = S1-84 | date = August 2008 | pmid = 18662584 | doi = 10.1016/j.jaci.2008.06.003 }}</ref>衍生自第二代抗組織胺藥[[鹽酸西替利嗪|鹽酸西替利嗪]]，為鹽酸西替利嗪[[外消旋混合物|外消旋混合物]]的左[[對映異構|對映異構]]體。

==醫療用途==
鹽酸左西替利嗪用於[[過敏|過敏]][[症狀|症狀]]，包括[[流淚|流淚]]、[[流鼻涕|流鼻涕]]、[[打噴嚏|打噴嚏]]，[[蕁麻疹|蕁麻疹]]及[[瘙癢|瘙癢]]。<ref>{{cite web | url = http://www.webmd.com/drugs/2/drug-148989/levocetirizine-oral/details | title = Levocetirizine Oral | publisher = [[WebMD|WebMD]]}}</ref>

== 副作用 ==
常見的副作用有頭痛、嗜睡、口乾、疲勞，發生機率等於或高於1%。

==相關製劑==
與[[二氫氯化物|二氫氯化物]](di-hydrochloride/二鹽酸鹽/<[[氫氯化物|氫氯化物]]/{{link-en|hydrochloride|Hydrochloride}}>)形成[[組合藥劑|組合藥劑]](combination drug)「好克敏」(Levocetirizine Dihydrochloride 5mg/長效型之抗過敏及抗組織胺藥、台灣南光化學製藥)。<ref>抗組織胺,Levocetirizine Dihydrochloride 5mg(長效型之抗過敏及抗組織胺藥)"[http://www.nangkuang.com.tw/index.php?option=product&lang=cht&task=pageinfo&id=199&belongid=198&index=0],南光化學製藥股份有限公司,retrieved Jan.26,2017.</ref>

==註釋==
{{reflist}}

== 參考文獻 ==
{{refbegin}}
*[http://www.gsk.tw/PDF/medicines/Xyzal.pdf Xyzal 驅異樂 全仿單]
{{refend}}

==參見==
*{{link-en|氫氯化物|Hydrochloride}}
*{{le|WebMD|WebMD}}
*{{le|組合藥劑|combination drug}}

==外部連結==
* [http://www.ucb.com/_up/ucb_com_products/documents/Xyzal_PI_%2012_2010.pdf  Full US prescribing information Xyzal® (levocetirizine dihydrochloride) tablets and oral solution (provided by UCB, December 2010, pdf file)]

{{Antihistamines}}
{{Histaminergics}}

[[Category:H1受體拮抗劑|Y]]